Drug Profile
Aliskiren/amlodipine/hydrochlorothiazide - Novartis
Alternative Names: Amlodipine/aliskiren/hydrochlorothiazide; Amlodipine/hydrochlorothiazide/aliskiren; Amturnide; Hydrochlorothiazide/aliskiren/amlodipine; Hydrochlorothiazide/amlodipine/aliskiren; Rasitrio; Tekturna®-amlo-HCTZ SPCLatest Information Update: 29 Mar 2019
Price :
$50
*
At a glance
- Originator Novartis
- Class Amides; Antihypertensives; Benzothiadiazines; Dihydropyridines; Fumarates; Small molecules
- Mechanism of Action Calcium channel antagonists; Renin inhibitors; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 29 Mar 2019 Chemical structure information added
- 12 Mar 2015 No recent reports on development identified - Phase-I for Hypertension (In volunteers) in India (PO)
- 12 Mar 2015 No recent reports on development identified - Phase-III for Hypertension in Australia, Canada, Israel, Turkey and Egypt (PO)